FURI | Fall 2018

Optimizing recombinant protein production for domain antibodies: proof-of-concept

Health icon, disabled. A red heart with a cardiac rhythm running through it.

Recent studies in traumatic brain injury (TBI) have found a temporal window where therapeutics on the nanometer scale can cross the blood-brain barrier and enter the parenchyma. Developing protein-based therapeutics is attractive for a number of reasons, yet, the production pipeline for high yield and consistent bioactive recombinant proteins is a major obstacle. This project directly addresses this issue and evaluates the potential to use Brevibacillus host to produce biologically active domain antibody proteins for future use in nanoparticle therapeutics.

Student researcher

Portrait of Glenna Embrador

Glenna Bea Embrador

Biomedical engineering

Hometown: Phoenix, Arizona

Graduation date: Spring 2020